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Medicinal chemistryWe report herein the synthesis, biological evaluation and docking analysis of a new series of methylsul-
fonyl, sulfamoyl acetamides and ethyl acetates that selectively inhibit cyclooxygenase-2 (COX-2) isoform.
Among the newly synthesized compounds, some of them were endowed with a good activity against
COX-2 and a good selectivity COX-2/COX-1 in vitro as well as a desirable analgesic activity in vivo, prov-
ing that replacement of the ester moiety with an amide group gave access to more stable derivatives,
characterized by a good COX-inhibition.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Cyclooxygenase (COX) enzyme plays a central role in the bio-
synthetic pathway of important biological mediators called prosta-
noids from arachidonic acid (AA). Although there are different
isoforms of COX (named COX-1 and COX-2) encoded by different
genes, there is a high homology sequence content in the derived
proteins (both isoforms share about 60% amino acid sequence).1
The most important differences between COX-1 and COX-2 are at
biological levels. While COX-1 is a constitutive enzyme, COX-2 is
mostly undetectable in tissues in normal conditions, while it is
induced during inflammation, hypoxia, and in many cancers.1,2Traditional non-steroidal anti-inflammatory drugs (t-NSAIDs)
can inhibit both COX-1 and COX-2 and are associated with a con-
sistent risk of serious adverse events, related to COX-1 inhibition.
While inflammation is reduced, stomach upset as well as ulcera-
tion and bleeding can be caused by the loss of the stomach lining.3
COX-2 selective inhibitors (Coxibs), such as celecoxib and rofec-
oxib, have been developed with the aim of reducing gastric irrita-
tion.3 Though, rofecoxib (Vioxx) and valdecoxib (Bextra) were
withdrawn from the market because of an increased incidence of
thrombotic events associated with long-term use.4
Nevertheless, some studies have suggested that rofecoxib’s
adverse cardiac events may be related to its chemical structure.
In fact, rofecoxib can readily form a reactive metabolite, which in
turn can disrupt essential cellular structure by reacting with nucle-
ophilic groups of various biologic molecules,5 suggesting that
adverse cardiac events might not be a class-related effect. There-
fore, novel scaffolds with selective COX-2 inhibitory activity are
needed.
We have previously reported several studies on the design, syn-
thesis and activity of pyrrole-based COX-2 inhibitors.6–12
Scheme 1. Synthesis of compounds 1–4. Reagents and conditions: (i) EDCI, DMAP,
CH2Cl2, amine, rt, 15 h.
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with IC50 in the nanomolar range. However, their in vivo profile,
was somehow lower than expected, indicating that the chemical
and enzymatic liability of these esters play a crucial role in the
pharmacokinetic fate of such a class of molecules.10 Therefore,
we present herein our efforts on developing more stable com-
pounds by replacing the ester moiety with an amide one.
At first, we have prepared propyl and isopropyl acetic amides
1–4 (Fig. 1) bearing a N1 phenyl ring decorated either at position
3 or position 4 with a fluorine atom, and a C5 p-methylsulfonyl
phenyl as reminiscent of previously synthesized compounds.11
Moreover, sulfamoylphenyl compounds 5–12 (Fig. 1), have also
been synthesized. The sulfamoylphenyl group has been introduced
grounding on the fact that several studies suggest that arylsulfon-
amides generally display a greater in vivo profile compared to that
of the corresponding aryl sulfones probably because the lower logP
contributes to improved absorption and bioavailability.13 In partic-
ular, compounds 5 and 6 (Fig. 1) bearing a decorated N1 phenyl
ring, a C5 sulfamoylphenyl moiety and an acetic ester chain at
position 3 have been prepared in order to evaluate the difference
in activity that could be given by the sulfamoyl moiety with
respect to acetic amides 1–4. Acetic amides 9–12 (Fig. 1) have been
then designed and synthesized by combining the introduction of
the sulfamoylphenyl moiety with the amide function. Finally, con-
sidering that both ester and amide derivatives could give rise
in vivo to the formation of corresponding acids, compounds 7
and 8 (Fig. 1) have been prepared and tested.
Compounds 1–12 were evaluated in vitro for their ability to
inhibit both COX-1 and COX-2 via an enzyme immunoassay (EIA)
and data were rationalized through docking simulations. Finally,
the analgesic activities of compounds 1–12 were evaluated in an
in vivo model of inflammatory pain.14
2. Results and discussion
2.1. Synthesis
Compounds 1–4 have been prepared according to the synthetic
pathway shown in Scheme 1. Briefly, 4-sulfonmethylphenyl acetic
acids 13a,b were obtained following the procedure previously
described.10 The coupling stage which led to acetamides 1–4 was
afforded in the presence of EDCI and DMAP and the appropriate
amine.
Compounds 5–12 have been synthesized according to the syn-
thetic pathway shown in Scheme 2. Briefly, pyrroles 14a,b have
been prepared as previously described.10 Generation of the carban-
ion with butyllithium on aryl methyl sulfones 14a,b, followed by
addition of iodomethyltrimethylsilane gave the trimethylsilylethyl
sulfone intermediates 15a,b. Desilylation with tetrabutylammo-
nium fluoride to the sulfinic acid salts followed by treatment withFigure 1. Chemical structurhydroxylamine-O-sulfonic acid in the microwave apparatus, gave
the desired arylsulfonamides 16a,b. Construction of the C3 acetic
chain of 5 and 6 was achieved by the regioselective acylation of
16a,b with ethoxalyl chloride and titanium tetrachloride followed
by reduction with triethylsilane in trifluoroacetic acid. Hydrolysis
with NaOH afforded acetic acids 7 and 8. Finally, 4-sulfamoylphe-
nyl acetamides 9–12 were afforded by means of EDCI as activating
agent and DMAP as covalent nucleophilic catalyst, then the active
species were reacted with the appropriate amine.
2.2. Biological and pharmacological studies
All the synthesized compounds were tested in vitro to assess
their inhibitory activities towards both cyclooxygenases (COX-1
and COX-2). Tests were performed exploiting the commercially
available COX Inhibitor Screening Assay (Cayman Chemical Com-
pany, Ann Arbor, MI, USA), which quantifies prostanoids produced
by reaction between COX and arachidonic acid via an enzyme
immunoassay. The inhibitory efficacy of the novel derivatives
was routinely estimated at concentration of 10 lM, and those com-
pounds found to be active were then tested at different concentra-
tions between 10 lM and 10 nM, to determine their IC50 values. As
shown in Table 1, some of the newly synthesized compounds
proved to inhibit COX-2 to a certain extent when tested at
10 lM.Within the methylsulfonylphenyl series (1–4), the presence
of the isopropylamide fragment determined the highest inhibitory
efficacy, as compounds 3 and 4 turned out to be more potent than
the propylamide counterparts, 1 and 2. In the sulfamoylphenyl ser-
ies, the highest inhibitory activity was guaranteed by the presence
of the ethyl ester function. Actually, compounds 5 (IC50
0.92 ± 0.05 lM) and 6 (IC50 1.07 ± 0.05 lM) proved to be potent
inhibitors. Hydrolysis of the ester moiety, to afford acetic acid
derivatives 7 and 8, and the replacement with an amide fragment,
as in compounds 9–12, lowered the observed efficacy against the
target protein. The most effective compounds 4–6 and 9, showed
no appreciable inhibitory properties against COX-1, thus proving
to be selective inhibitors of the inducible form of this enzyme.es of compounds 1–12.
Scheme 2. Synthesis of compounds 5–12. Reagents and conditions: (i) n-BuLi, DIPA, THF, 78 C, 30 min, then iodomethyltrimethylsilane, rt, 1.5 h; (ii) TBAF, hexane, 15 min,
MW (120 C, 150 W, 170 psi), then NaAc, hydroxylamine-O-sulfonic acid, 10 min, MW (50 C, 150 W, 170 psi); (iii) EtOCOCOCl, TiCl4, CH2Cl2, rt, 4 h; (iv) Et3SiH, TFA, rt, 2 h; (v)
1 N NaOH, MeOH, reflux, 2 h; (vi) EDCI, DMAP, CH2Cl2, amine, rt, 15 h.
Table 1
In vitro inhibition of COX-1 and COX-2 by compounds 1–12
Compd % of Inhibition (10 lM) IC50 (COX-2, lMa)
COX-1 COX-2
1 n.t.b 43 n.d.c
2 n.t.b 65 n.d.c
3 n.t.b 74 7.00 ± 0.34
4 36 95 4.91 ± 0.20
5 n.a.d 89 0.92 ± 0.05
6 n.a.d 82 1.07 ± 0.05
7 n.t.b 65 n.d.c
8 n.t.b 65 n.d.c
9 n.a.d 96 5.78±0.30
10 n.t.b 62 n.d.c
11 n.t.b 49 n.d.c
12 n.t.b 48 n.d.c
SC-56015 100 - —
DuP-69716 — 100 —
a IC50 values, means ± SD, represent the concentration required to produce 50%
enzyme inhibition.
b Not tested.
c Not determined.
d Not active, no inhibition was observed at 10 lM of test compound.
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in vivomodel of inflammatory pain14 bymeasuring the reduction of
writhes induced by intra-peritoneal injections of acetic acid solu-
tion in mice. Compounds 1–12 were orally administered (po) (1–
40 mg/kg dose range) 30 min before the induction of writhes.
Results are reported as the number of writhes and as a percentage
of writhes reductionwith respect to vehicle-treatedmice in Table 2.
Compound 6 (R = 4-F; X = –C2H5) showed the best efficacy in
inducing writhes reduction (62%) when dosed at 40 mg/kg, while
its efficacy was dose dependent within the range of 10–40 mg/
kg. The meta-fluoro analog 5, which showed similar activity
in vitro, was much less effective in reducing the number of writhes
in vivo. The same trend can be seen for the acids 7 and 8. In the
methylsulfonyl phenyl series (1–4), compound 4 proved to be the
best one in reducing the number of writhes (48.7%), it is possibleto observe a significant decrease of activity when going from iso-
propyl to propyl amides (3 and 4 vs 1 and 2), this could depend
on the fact that a more branched chain is more stable at metabolic
level. Finally, sulfamoylphenyl acetamides 9–12 proved a moder-
ate efficacy in reducing the number of writhes with the exception
of compound 9. In fact, nonetheless it proved to be the best com-
pound within the sulfamoylphenyl series in vitro (IC50
5.78 ± 0.30 lM) it showed nearly the lowest activity in vivo with
only 12% of writhes reduction.
2.3. Structure-based studies
2.3.1. Docking assessment
Before performing any docking study, the most suitable docking
program within a series of 8 program/scoring combinations func-
tion was assessed by a previously described cross-docking proto-
col17,18 applied on the available experimental co-crystallized
complexes for either COX-1 (18 complexes, Table 3) or COX-2
(14 complexes, Table 4). Briefly, each energy minimized COX com-
plex was divided into ligand and protein (see Section 4). The sepa-
rated ligand conformations were randomized and docked into all
proteins (cross-docking), except for the native ones. The resulting
lowest energy pose within all the docking runs were then com-
pared to the experimental ones, and the root mean square devia-
tions (RMSDs) were calculated (Tables 1 and 2). The calculated
docking accuracy percentages (DAs%)19 revealed Surflex-Dock20,21
as the most suitable program to dock a modeled ligand into
COX-1 showing DAs% of 58.33 while Vina performed the best for
COX-2 (DA% = 67.86). In the case of COX-1, Autodock performed
the same DA%, but the error dispersion as calculated by the RMSD
standard deviation was slightly higher than that of displayed by
Surflex-Dock, with almost the same average values, furthermore
Surflex-Dock is about 10 times faster than Autodock. These results
clearly indicate that in the presence of a ligand able to bind either
COX-1 or COX-2, the most suitable program need to be chosen ad-
hoc. Based on the docking assessment Surflex-Dock and Vina were
able to suggest their correct binding mode with the lowest errors
for COX-1 and COX-2, respectively.
Table 2
Effect of 1–12, celecoxib, and vehicle (CMC) in the mouse abdominal constriction test (acetic acid 0.6%)
Treatment No. of mice Dose (mg/kg po) No. or writhes Writhes reduction (%)
CMC 28 30.4 ± 1.6
1 5 10 26.7 ± 2.5 12.2
1 5 30 27.4 ± 3.3 9.9
2 6 1 30.6 ± 3.7 —
2 7 3 27.3 ± 2.9 10.2
2 6 10 21.3 ± 3.4* 29.9
3 5 10 29.3 ± 2.8 3.6
3 5 30 22.7 ± 2.9* 25.3
4 6 10 26.7 ± 3.6 12.2
4 5 30 15.6 ± 3.2* 48.7
5 5 10 22.5 ± 2.5^ 26.0
5 5 30 20.16 ± 2.8* 33.5
6 8 10 29.2 ± 3.1 10.4
6 8 20 24.5 ± 3.6* 24.8
6 8 40 12.3 ± 2.5* 62.3
7 5 10 27.5 ± 2.8 9.5
7 6 30 31.3 ± 3.3 —
8 7 10 27.1 ± 3.5 16.9
8 8 20 21.8 ± 3.2* 33.1
8 9 40 16.63 ± 3.1* 49.1
9 5 10 32.9 ± 4.2 —
9 5 30 26.7 ± 3.7 12.2
10 6 3 29.2 ± 3.3 3.9
10 5 10 27.9 ± 4.1 8.3
10 6 30 18.5 ± 3.6* 39.1
11 6 3 26.9 ± 3.1 11.5
11 5 10 21.5 ± 3.2* 29.3
11 5 30 20.8 ± 3.3* 31.6
12 6 3 25.5 ± 3.8 16.1
12 5 10 19.3 ± 2.5* 36.5
12 6 30 17.1 ± 3.5* 43.7
Celecoxib 12 10 12.96 ± 2.1* 57.4
^ P <0.05.
* P <0.01 in comparison with CMC treated group.
Table 3
Docking assessment for COX-1
PDBa Plants Surflex-Dock Vina Autodock Paradocks
Chemplpe Plp95e plpe Pscoree Pmf04e
2AYL 1.87 3.45 3.23 0.64 0.66 0.60 3.18 0.45
1CQE 1.08 3.82 3.54 0.44 1.71 1.67 3.41 0.46
1DIY 0.92 11.15 3.68 1.21 3.15 3.87 3.48 3.31
1EBV 4.38 4.27 4.38 2.29 4.02 13.71 4.31 6.38
1EQG 0.59 7.19 4.20 0.53 6.56 0.66 3.06 1.80
1EQH 0.67 3.75 3.71 1.70 3.16 0.75 3.37 0.50
1FE2 1.47 3.82 1.43 10.18 1.39 1.52 17.83 1.90
1HT5 3.97 3.99 3.97 1.95 3.15 1.91 3.03 0.91
1HT8 0.91 7.14 7.14 1.98 4.68 2.18 4.06 4.65
1PGE 7.10 7.27 7.11 0.86 1.67 4.50 4.18 2.70
1PGF 6.58 6.56 6.57 5.47 3.28 3.27 3.71 2.63
1PGG 6.90 3.55 3.56 6.18 3.55 3.56 6.63 6.50
1PTH 7.27 7.67 7.27 3.97 7.25 1.06 8.35 8.35
2OYE 2.39 2.36 2.10 4.12 2.84 2.25 3.65 3.11
2OYU 4.22 4.25 4.27 5.37 2.88 2.38 2.45 5.38
3N8W 3.10 3.72 3.37 0.54 2.86 0.64 2.94 0.89
3N8X 0.74 5.93 5.95 4.82 4.89 6.72 1.05 0.99
3N8Z 0.63 3.68 3.43 1.67 1.74 1.62 3.18 0.41
DA %b 52.78 2.78 8.33 58.33 36.11 58.33 11.11 55.56
Averagec 3.04 5.20 4.38 3.00 3.30 2.94 4.55 2.85
StDevd 2.49 2.21 1.72 2.62 1.72 3.13 3.67 2.45
All values are reported as RMSD.
a PDB entry codes.
b Docking accuracy as defined in the Section 4.
c Average RMSD value.
d Standard deviation value.
e The scoring function names as implemented in the docking programs.
S. Consalvi et al. / Bioorg. Med. Chem. 23 (2015) 810–820 813
Table 4
Docking assessment for COX-2
PDBa Plants Surflex-Dock Vina Autodock Paradocks
Chemplpe Plp95e plpe Pscoree Pmf04e
1PXX 6.79 6.942 5.783 5.72 7.60 5.73 1.68 1.32
3LN0 0.76 0.764 1.529 5.28 1.16 5.25 1.18 1.15
3LN1 1.05 0.915 0.631 0.83 0.83 1.05 0.83 0.90
3MQE 4.78 4.489 4.492 6.16 3.00 6.66 4.82 0.95
3NT1 0.28 0.586 0.323 0.49 0.29 0.76 0.68 6.67
3NTB 0.64 4.5 0.471 1.88 0.73 0.62 6.47 1.23
3NTG 3.60 4.538 3.71 1.02 3.74 1.04 3.75 3.23
3Q7D 0.36 4.886 1.923 0.14 0.59 0.29 6.31 6.47
3QMO 0.89 1.09 0.907 1.03 0.72 5.07 0.92 1.03
3RR3 0.68 0.718 1.006 0.54 0.46 0.99 1.73 1.60
4E1G 7.03 6.809 6.923 8.98 6.91 5.65 14.83 11.31
4FM5 1.78 1.777 2.072 0.44 1.80 1.65 0.90 0.37
4M10 7.25 7.276 5.834 1.77 1.45 7.40 7.61 1.96
4M11 7.27 7.378 7.328 5.65 5.20 8.32 7.32 6.90
DA %b 57.14 42.86 53.57 64.29 67.86 50.00 50.00 64.29
Averagec 3.08 3.76 3.07 2.85 2.46 3.60 4.22 3.22
StDevd 2.91 2.71 2.55 2.87 2.48 2.93 4.03 3.29
All values are reported as RMSD.
a PDB entry codes.
b Docking accuracy as defined in the Section 4.
c Average RMSD value.
d Standard deviation value.
e The scoring function names as implemented in the docking programs.
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As Surflex-Dock and Vina performed the best, the titled com-
pounds were all cross-docked by means of these programs. In par-
ticular, all the compounds found active against either COX-1 or
COX-2 enzymes (Tables 1 and 5) were modeled and cross-docked
into all the available COX-1/COX-2 experimental structures follow-
ing the same protocol as in the docking assessment. The lowest
energy poses were selected17 as the likely binding modes for the
newly synthesized compounds. Compound 4 was the only one
found with an appreciable inhibitory activity against COX-1 (36%
at 10 lM) and its lowest energy bound pose was found in the pro-
teins 2OYU (Fig. 2A). On the contrary, all the compounds were
selectively active against COX-2 at different levels and therefore
were all cross-docked. Eight times (compounds 1, 2, 6, 7, 8, 9, 10
and 11, Fig. 2B) out of twelve, 3LNI was the preferred binding site,
while three times (compounds 3, 4 and 12, Fig. 2C) was selected
the protein extracted from the 2MQE complex and compound 5
was found to best bind in 3QMO (Fig. 2D). As a matter of fact,
the Vina predicted affinities against COX-2 for compounds 4, 5, 6
and 9 did not correlate with the experimental ones listed in Table 1,
likely due to the high redundancy in the scoring function associ-
ated to any docking program. On the other hand, comparing the
Vina average predicted affinities, the scoring function correctly
indicated compound 4 as more active against COX-2 than against
COX-1 (Table 4). In the latter case, the enzymes’ structural differ-
ences are somehow recognized by the scoring function and corrob-
orate the previous statement. COX-2 active compounds were all
docked, and their bindings examined. As shown in Figure 2B–DTable 5
Predicted average affinities for compounds docked compounds in COX-1/COX-2 enzymes
Compd Preferred COX1 protein PDB code Average predicted activity (kcal/mo
4 2OYU 5.57**
5 ND* —
6 ND* —
9 ND* —
In the COX-1 and COX-2 column are reported the compounds’ preferred binding sites P
* ND: not docked.
** Surflex-Dock pose rescored by Vina.the COX-2 active derivatives 1–12 share a common binding mode
(BM). Being compound 4 the only one exerting some activity
against either enzyme BM inspection into COX-1 and COX-2 were
focused on this compound. Nevertheless BM analysis revealed that
compound 4 adopt similar binding modes into either isoenzyme.
The main difference in binding relies on the fact that in COX-2
Arg513 side chain in the selectivity pocket5 makes a moderate
hydrogen bond22 with the sulfonyl group (distance NCOX-2-
Arg513O4-(SO2) = 3.10 Å, Fig. 3), which is missing in COX-1
being residue 513 an histidine with a shorter and less flexible side
chain not able to make any hydrogen bond with 4-sulfonyl group.
Surprisingly, this observation is in good agreement with the
1.23 kcal/mol binding energy difference recorded for compound 4
in both COX-1 and COX-2 (Table 5). Furthermore, the 4-SO2
hydrogen bonding oxygen is perfectly superimposing its analog
atom in Celecoxib SO2 moiety as found in the bound crystal
(PDB entry code 3LNI, Fig. 3). Regarding the other titled deriva-
tives, the overall binding modes are quite overlapping, and any
further inspection would be redundant (Fig. 2). This common
BM confirms the reproducibility of the docking protocol when
slightly structural differences occur. The herein application of
Surflex-Dock/Vina and the cross-docking protocol are in good
agreement with the earlier observations in which a different dock-
ing program (Autodock 3.0.5) and only one COX-2 structure (pdb
entry code 1CX2) were used. For comparison purposes, the latest
version of Autodock was applied in a parallel to cross-dock 1–12
and only slightly binding mode differences were observed (not
shown).l) Preferred COX2 protein PDB code Average predicted activity (kcal/mol)
3MQE 6.80
3QMO 7.82
3LN1 7.59
3LN1 8.20
DB codes.
Figure 2. The new compounds docked into COX1 and COX-2. (A) 4 in COX-1 (2OYU, colored in light gray and residue labeled in red); (B) 1, 2, 6, 7, 8, 9, 10 and 11 in 3LN1
(colored in gold and residues labeled in black); (C) 3, 4 and 12 in 2MQE (colored in cyan and residues labeled in black); (D) 5 in 3QMO (colored in green and residues labeled in
black). The figures were generated by the means of UCSF Chimera 1.9.25
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The development of a novel class of COX-2 selective inhibitors
has been reported. Among the newly synthesized compounds,
some of them were endowed with a good activity against COX-2
and a good selectivity COX-2/COX-1 in vitro and showed a good
analgesic activity in vivo, proving that replacement of the ester
moiety with an amide group gave access to more stable deriva-
tives, characterized by a good COX-inhibiting profile. Comparing
the same dosage (10 mg/kg), sulfamoyl phenyl derivatives proved
to be more active than the methylsulfonyl analogues, showing thatthe introduction of this group led to compounds characterized by a
better in vivo profile and a greater activity at lower dosages, prob-
ably because of their improved bioavailability. Further studies are
needed to evaluate the influence of that moiety on solubility and to
assess the pharmacokinetic profile.
Finally, binding mode analyses on compound 1–12 to COX-2
confirmed the structure-based studies performed on pyrrole deriv-
atives we previously reported. The cross-docking protocol
employed as much as possible the available experimental struc-
tural information representing the basis for future applications
such as development of predictive 3-D QSAR and/or COMBINEr
Figure 3. Docked conformation of 4 (light blue colored carbon atoms) in COX-1 (2OUY, gray surface, and residues labeled in red) and the conformation of 4 (green colored
carbon atoms) in COX-2 (3MQE, cyan surface, residues labeled in black). The moderate hydrogen bond (3.10 Å) between Arg513COX-2 (in stick cyan colored carbon atoms) and
CH3SO2 of 4 is depicted in black dashed line. For comparison His513COX-1 (in stick gray colored carbon atoms) is also displayed. The figure was generated by the means of UCSF
Chimera 1.9.12 For comparison purpose, the co-crystallized celecoxib is also displayed (purple colored carbon atoms).
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to fill the lack of correct activity prediction trend by the associated
docking program scoring function.4. Experimental section
4.1. Chemistry
All chemicals used were of reagent grade. Yields refer to puri-
fied products and are not optimized. A CEM Discovery microwave
system apparatus was used for microwaved reactions. Melting
points were determined in open capillaries on a Gallenkamp appa-
ratus and were uncorrected. Sigma–Aldrich silica gel 60 (230–
400 mesh) was used for column chromatography. Merck TLC plates
(silica gel 60 F 254) were used for thin-layer chromatography
(TLC). 13C NMR and 1H NMR spectra were recorded with a Bruker
AC 400 spectrometer in the indicated solvent (TMS as the internal
standard). The values of the chemical shifts are expressed in d.
Mass spectra were recorded on an API-TOF Mariner by Perspective
Biosystem (Stratford, Texas, USA).4.1.1. General procedure for the preparation of
4-methylsulfonylphenyl acetamides 1–4
To a solution of the appropriate acid (13a,b) (0.51 mmol) in
DCM (10 mL), the suitable amine (2.04 mmol), DMAP (0.61 mmol,
00.07 g) and EDCI (0.82 mmol, 0.16 g) were added in sequence.The reaction mixture was stirred at room temperature for
15 h then diluted with water, and the two phases were separated
with dichloromethane. The organic layers were washed with 2 N
HCl, NaHCO3 saturated solution and brine, and then dried over
Na2SO4, filtered and concentrated in vacuo. The obtained crude
products were purified by column chromatography on silica gel
using cyclohexane/ethyl acetate 1:1 (v/v), as eluent. After recrys-
tallization from ethyl acetate the desired products 1–4 were
obtained.
4.1.1.1. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)
phenyl)-1H-pyrrol-3-yl)-N-propylacetamide (1). White
powder, mp 164 C (yield 80%). 1H NMR (400 MHz, DMSO-d6) d
ppm: 7.87 (t, 1H, NH), 7.68 (d, 2H, –C–CH–CH), 7.51–7.46 (m, 1H,
CH–CH–CH), 7.31–7.29 (m, 1H, C–CH–CH), 7.27–7.25 (m, 1H, N–
C–CH–C–F), 7.18 (d, 2H, S–C–CH–CH), 7.04 (d, 1H, CH–CH–C–F),
6.51 (s, 1H, CH pyrrolic), 3.24 (s, 2H, C–CH2–CO), 3.14 (s,
3H, CH3–SO2), 3.01 (m, 2H, N–CH2–CH2), 2.02 (s, 3H, CH3 pyrrolic),
1.44–1.39 (sest, 2H, CH2–CH2–CH3), 0.84 (t, 3H, CH2–CH3). 13C
NMR (100 MHz, DMSO-d6) d (ppm): 171.6 (CH–CO–NH), 161.4
(C–F), 144.4 (CH–C–CH), 143.7 (N–C–CH), 141.3 (S–C), 134.6
(N–C–C), 131.2 (CH–CH–CH), 128.8 (CH–C–S), 128.4 (CH–CH–C),
125.8 (N–C–CH3), 121.0 (CH–C–CH2), 116.3 (C–CH–CH),
113.5 (CH pyrrolic), 112.7 (CH–C–C–F), 107.2 (F–C–CH–C–N),
47.3 (CH3–SO2), 42.6 (NH–CH2), 34.0 (CH2CO), 23.4 (CH2CH2CH3),
14.6 (CH2–CH3), 10.0 (CH3 pyrrolic). MS-ESI: m/z 451.15
[M+Na]+.
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phenyl)-1H-pyrrol-3-yl)-N-propylacetamide (2). White pow-
der, mp 168 C (yield 80%). 1H NMR (400 MHz, DMSO-d6) d ppm:
7.86 (t, 1H, NH), 7.69 (d, 2H, –C–CH–CH), 7.32–7.30 (m, 4H, H aro-
matic), 7.19 (d, 2H, S–C–CH–CH), 6.52 (s, 1H, CH pyrrolic), 3.26 (s,
2H, C–CH2–CO), 3.15 (s, 3H, CH3–SO2), 3.03 (m, 2H, N–CH2–CH2),
2.01 (s, 3H, CH3 pyrrolic), 1.45–1.41 (sest, 2H, CH2–CH2–CH3),
0.86 (t, 3H, CH2–CH3). 13C NMR (100 MHz, DMSO-d6) d (ppm):
171.6 (CH–CO–NH), 159.2 (C–F), 146.2 (N–C–CH), 144.0 (CH–C–
CH), 141.3 (S–C), 134.0, (N–C–C), 128.6 (CH–C–S), 128.0 (CH–CH–
C), 125.8 (N–C–CH3), 121.9 (CH–CH–C–N), 121.2 (CH–C–CH2),
115.8 (CH–CH–C–F), 112.9 (CH pyrrolic), 46.3 (CH3–SO2), 41.9
(NH–CH2), 34.3 (CH2CO), 23.1 (CH2CH2CH3), 11.00 (CH2–CH3), 9.8
(CH3 pyrrolic). MS-ESI: m/z 451.15 [M+Na]+.
4.1.1.3. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)
phenyl)-1H-pyrrol-3-yl)-N-isopropylacetamide (3). White
powder, mp 175 C (yield 80%). 1H NMR (400 MHz, DMSO-d6) d
ppm: 7.80 (d, 1H, NH),7.69 (d, 2H, –C–CH–CH), 7.51–7.46 (m, 1H,
CH–CH–CH), 7.30–7.26 (m, 1H, C–CH–CH), 7.24–7.21 (m, 1H, N–
C–CH–C–F) 7.17 (d, 2H, S–C–CH–CH), 7.03 (d, 1H, CH–CH–C–F),
6.50 (s, 1H, CH pyrrolic), 3.86–3.78 (set, 1H, CH3–CH–CH3), 3.21
(s, 2H, C–CH2–CO), 3.14 (s, 3H, CH3–SO2), 2.02 (s, 3H, CH3 pyrrolic),
1.06 (d, 6H, CH–CH3). 13C NMR (100 MHz, DMSO-d6) d (ppm):
171.8 (CH–CO–NH), 159.9 (C–F), 144.2 (CH–C–CH), 143.0 (N–C–
CH), 140.4 (S–C), 134.4 (N–C–C), 130.0 (CH–CH–CH), 128.3 (CH–
C–S), 128.0 (C–CH–CH), 124.8 (N–C–CH3), 120.6 (CH–C–CH2),
115.8 (CH–CH–C–N), 113.1 (CH pyrrolic), 112.3 (CH–CH–C–F),
106.5 (F–C–CH–C–N), 46.7 (CH3–SO2), 44.3 (CH3–CH–CH3), 33.5
(CH2CO), 23.1 (CH3–CH), 9.7 (CH3 pyrrolic). MS-ESI: m/z 451.15
[M+Na]+.
4.1.1.4. 2-(1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)
phenyl)-1H-pyrrol-3-yl)-N-isopropylacetamide (4). White
powder, mp 178 C (yield 80%). 1H NMR (400 MHz, DMSO-d6) d
ppm: 7.76 (t, 1H, NH), 7.68 (d, 2H, –C–CH–CH), 7.30–7.28 (m, 4H,
H aromatic), 7.17 (d, 2H, S–C–CH–CH), 6.49 (s, 1H, CH pyrrolic),
3.85–3.79 (sest, 1H, CH3–CH–CH3), 3.20 (s, 2H, C–CH2–CO), 3.13
(s, 3H, CH3–SO2), 1.98 (s, 3H, CH3 pyrrolic), 1.05 (d, 6H, CH–CH3).
13C NMR (100 MHz, DMSO-d6) d (ppm): 171.9 (CH–CO–NH),
160.0 (C–F), 147.3 (CH–C–N), 145.1 (CH–C–CH), 141.5 (S–C),
135.2 (N–C–C), 129.3 (CH–C–S), 128.5 (C–CH–CH), 126.3 (N–C–
CH3), 122.2 9 (CH–CH–C–N), 121.3 (CH–C–CH2), 116.9 (CH–CH–
C–F), 114.3 (CH pyrrolic), 48.2 (CH3–SO2), 44.0 (CH3–CH–CH3),
35.1 (CH2CO), 23.5 (CH3–CH), 10.2 (CH3 pyrrolic). MS-ESI: m/z
451.15 [M+Na]+.
4.1.2. General procedure for preparation of 2-methyl-5-(4-((2-
(trimethylsilyl) ethyl)sulfonyl) phenyl)-1H-pyrroles 15a,b
A butyllithium solution (3.38 mmol, 1.38 mL, 2.5 M in hexane)
was slowly added to a mixture of DIPA (4.03 mmol, 0.58 mL) in
dry THF (10 mL), at 0 C and under nitrogen flow. The reaction
mixture was stirred for thirty minutes and was cooled down
to 78 C, then a solution of the suitable pyrrole (14a,b)
(2.9 mmol) in dry THF (10 mL) was added dropwise. After 1,5-
h stirring, iodomethyltrimethylsilane (4.03 mmol, 0.61 mL) was
added and the mixture was allowed to warm up to room tem-
perature and to stir for 15 h. The reaction mixture was quenched
with water and the pH was adjusted (pH = 2) with 1 N HCl. The
resulting mixture was extracted with ethyl acetate and the
organic layers were washed with brine and dried over Na2SO4.
After concentration in vacuo the crude products were purified
by chromatography on silica gel using cyclohexane/ethylacetate
15:1 (v/v) as eluent to give the expected products 15a,b as white
powder.4.1.2.1. 1-(3-Fluorophenyl)-2-methyl-5-(4-((2-(trimethylsilyl)
ethyl) sulfonyl)phenyl)-1H-pyrrole (15a). White powder,
mp 78 C (60% yield). 1H NMR (400 MHz, CDCl3) d (ppm): 7.66 (d,
2H, –C–CH–CH), 7.40–7.36 (m, 1H, CH–CH–CH), 7.20 (d, 2H, S–C–
CH–CH), 7.14–7.09 (m, 1H, N–C–CH–C–F), 6.97–6.95 (m, 1H, C–
CH–CH), 6.91–6.89 (m, 1H, CH–CH–C–F), 6.52 (d, 1H, CH pyrrolic),
6.14 (d,1H, CH pyrrolic), 2.98–2.93 (m, 2H, CH2–CH2–SO2), 2.18 (s,
3H, CH3 pyrrolic), 0.92–0.88 (m, 2H, Si–CH2–CH2), 0.03 (s, 9H, Si–
CH3). 13C NMR (100 MHz, CDCl3): d (ppm) 163.2 (C–F), 144.8
(CH–C–CH), 142.9 (N–C–CH), 139.3 (S–C), 133.2 (N–C–C), 131.5
(CH–CH–CH), 129.1 (CH–C–S), 128.7 (N–C–CH3), 128.3 (C–CH–
CH), 117.5 (N–C–CH–CH), 112.6 (C–CH–CH pyrrolic), 112.1 (CH–
CH–C–F), 110.3 (CH–CH–C–CH3 pyrrolic), 108.6 (F–C–CH–C–N),
58.4 (SO2–CH2), 15.3 (CH2–CH2–Si), 13.2 (CH3 pyrrolic), 2.1 (Si–
CH3). MS-ESI: m/z 438.13 [M+Na]+.
4.1.2.2. 1-(4-Fluorophenyl)-2-methyl-5-(4-((2-(trimethylsilyl)-
ethyl) sulfonyl)phenyl)-1H-pyrrole (15b). White powder, mp
75 C (60% yield). 1H NMR (400 MHz, CDCl3) d (ppm): 7.63 (d, 2H,
–C–CH–CH), 7.15–7.08 (m, 6H, H aromatic), 6.51 (d, 1H, CH pyrrolic),
6.13 (d, 1H, CH pyrrolic), 2.98–2.93 (m, 2H, CH2–CH2–SO2), 2.13 (s,
3H, CH3 pyrrolic), 0.93–0.86 (m, 2H, Si–CH2–CH2), 0.03 (s, 9H,
Si–CH3). 13C NMR (100MHz, CDCl3) d (ppm): 160.1 (C–F), 146.3
(N–C–CH), 142.8 (CH–C–CH), 139.3 (S–C), 133.2 (N–C–C), 128.6
(CH–CH–C–S), 128.3 (N–C–CH3), 127.9 (C–CH–CH), 122.4 (N–C–
CH–CH), 117.9 (CH–CH–C–F), 113.1 (C–CH–CH pyrrolic), 110.2
(CH–CH–C–CH3 pyrrolic), 58.2 (SO2–CH2), 15.4 (CH2–CH2–Si), 13.3
(CH3 pyrrolic), 2.1 (Si–CH3). MS-ESI: m/z 438.13 [M+Na]+.
4.1.3. General procedure for the preparation of sulfonamide
pyrroles 16a,b
A solution of tetrabutylammonium fluoride in hexane
(3,6 mmol, 3.6 mL) was added to the appropriate trimethylsilylpyr-
role 15a,b (1.2 mmol) and was microwave irradiated at 120 C for
15 min (power 150 W, pressure 170 psi). A solution of sodium ace-
tate (3,6 mmol, 0.29 g) in water (3.6 mL) and hydroxylamine-O-
sulfonic acid (3.6 mmol, 0.41 g) was then added; the mixture was
irradiated again for 10 min at 50 C (power 150 W, pressure
170 psi). The reaction mixture was then quenched with water,
extracted with ethyl acetate and then washed with brine. The
organic layers were dried over Na2SO4, filtered off and concen-
trated in vacuo. The obtained crude products were purified by
chromatography on silica gel using petroleum ether/ethylacetate
2:1 (v/v) as eluent. After recrystallization from diethyl ether the
expected products 16a,b were obtained.
4.1.3.1. 4-(1-(3-Fluorophenyl)-5-methyl-1H-pyrrol-2-yl) ben-
zenesulfonamide (16a). White powder, mp 115 C (80%
yield). 1H NMR (400 MHz, CDCl3) d (ppm): 7.67 (d, 2H, –C–CH–
CH), 7.46–7.42 (m, 1H, CH–CH–CH), 7.28–7.26 (m, 1H, C–CH–CH),
7.07–7.03 (m, 1H, N–C–CH–C–F), 6.94–6.91 (m, 2H, S–C–CH–CH),
6.89–6.86 (m, 1H, CH–CH–C–F), 6.48 (d, 1H, CH pyrrolic), 6.15 (d,
1H, CH pyrrolic), 4.81 (s, broad, 2H, NH2), 2.14 (s, 3H, CH3 pyrrolic).
13C NMR (100 MHz, CDCl3) d (ppm): 163.3(C–F), 145.6 (S–C), 143.1
(N–C–CH), 141.9 (CH–C–CH), 134.3 (N–C–C), 131.6 (CH–CH–CH),
129.1 (N–C–CH3), 128.3 (CH–C–S), 126.9 (C–CH–CH), 116.9 (N–C–
CH–CH), 113.2 (C–CH–CH pyrrolic), 112.9 (CH–CH–C–F), 110.4
(CH–CH–C–CH3 pyrrolic), 108.1 (F–C–CH–C–N), 12.6 (CH3 pyrrolic).
MS-ESI: m/z 353.07 [M+Na]+.
4.1.3.2. 4-(1-(4-Fluorophenyl)-5-methyl-1H-pyrrol-2-yl) ben-
zenesulfonamide (16b). White powder, mp 126 C (80% yield).
1H NMR (400 MHz, CDCl3) d (ppm): 7.67 (d, 2H, –C–CH–CH), 7.13–
7.09 (m, 6H, H aromatic), 6.48 (d, 1H, CH pyrrolic), 6.13 (d, 1H, CH
pyrrolic), 4.71 (s broad, 2H, NH2), 2.13 (s, 3H, CH3 pyrrolic). 13C
NMR (100 MHz, CDCl3) d (ppm): 163.8 (C–F), 146.1 (N–C–CH),
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129.1 (CH–CH–C–S), 128.8 (C–CH–CH), 121.4 (N–C–CH–CH),
116.9 (CH–CH–C–F), 114.2 (C–CH–CH pyrrolic), 108.8 (CH–CH–C–
CH3 pyrrolic), 12.8 (CH3 pyrrolic). MS-ESI: m/z 353.07 [M+Na]+.
4.1.4. General procedure for the preparation of 1,5-diarylpyrrol-
3-glyoxylic esters 17a,b
Ethoxalyl chloride (3.0 mmol) and TiCl4 (3.0 mmol) were added
in sequence, at 0 C and under nitrogen atmosphere, to a solution
of the appropriate pyrrole (16a,b) (3.0 mmol) in dry dichlorometh-
ane (10 mL). The resulting solution was allowed to warm up to
room temperature and stirred for 4 h. The mixture was then
diluted with water and the two phases were separated with dichlo-
romethane. The organic layers were washed with brine, dried over
Na2SO4, and evaporated in vacuo, then the crude material was
purified by chromatography on silica gel employing petroleum
ether/ethyl acetate, 3:1 (v/v) as eluent. After recrystallization from
diethyl ether the expected products 17a,b were obtained.
4.1.4.1. Ethyl-2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)-2-oxoacetate (17a). White powder,
mp 175 C, (60% yield). 1H NMR (400 MHz, CDCl3) d ppm: 7.75
(d, 2H, –C–CH–CH), 7.45–7.43 (m, 1H, CH–CH–CH), 7.20–7.19 (m,
1H, N–C–CH–C–F), 7.17 (d, 2H, S–C–CH–CH), 7.07 (s, 1H, CH pyrro-
lic), 6.97 (d, 1H, C–CH–CH), 6.89 (m, 1H, CH–CH–C–F), 4.75 (s
broad, 2H, NH2), 4.42 (q, 2H, OCH2–CH3), 2.47 (s, 3H, CH3 pyrrolic),
1.43 (t, 3H, CH2CH3). 13C NMR (100 MHz, CDCl3) d (ppm): 183.2
(CH–CO), 166.2 (CO–O), 162.9 (C–F), 145.8 (S–C), 144.2 (N–C–CH),
142.3 (CH–C–CH), 135.2 (N–C–CH3), 133.4 (N–C–C), 131.4 (CH–
CH–CH), 129.3 (CH–C–S), 128.6 (C–CH–CH), 117.1 (N–C–CH–CH),
113.7 (CH–CH–C–F), 112.1 (C–CO pyrrolic), 107.2 (CH pyrrolic),
106.8 (F–C–CH–C–N), 61.7 (O–CH2CH3), 13.6 (CH2–CH3), 12.8
(CH3 pyrrolic). MS-ESI: m/z 453.09 [M+Na]+.
4.1.4.2. Ethyl-2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)-2-oxoacetate (17b). White powder,
mp 177 C (60% yield). 1H NMR (400 MHz, CDCl3) d ppm: 7.72 (d,
2H, –C–CH–CH), 7.16–7.13 (m, 6H, H aromatic), 7.05 (s, 1H, CH pyr-
rolic), 4.72 (s broad, 2H, NH2), 4.41 (q, 2H, OCH2–CH3), 2.44 (s, 3H,
CH3 pyrrolic), 1.42 (t, 3H, CH2CH3). 13C NMR (100 MHz, CDCl3) d
(ppm): 183.0 (CH–CO), 166.4 (CO–O), 162.9 (C–F), 146.4 (S–C),
143.8 (N–C–CH), 142.3 (CH–C–CH), 134.9 (N–C–CH3), 131.4 (N–
C–C), 128.2 (CH–C–S), 127.5 (C–CH–CH), 121.3 (N–C–CH–CH),
117.6 (CH–CH–C–F), 112.8 (C–CO pyrrolic), 106.5 (CH pyrrolic),
62.1 (O–CH2CH3), 13.8 (CH2–CH3), 12.7 (CH3 pyrrolic). MS-ESI: m/
z 453.09 [M+Na]+.
4.1.5. General procedure for the preparation of 1,5-diarylpyrrol
acetic esters 5 and 6
To a solution of the appropriate glyoxylic ester (17a,b)
(2.3 mmol) in trifluoroacetic acid (16.1 mL) at 0 C and under nitro-
gen atmosphere, triethylsilane (6.9 mmol, 1.1 mL) was slowly added.
The mixture was allowed to warm up to room temperature and stir-
red for two hours, then was diluted with water and was made alka-
line (pH = 12) using a solution of 40% aqueous ammonia. The
mixture was then extracted with dichloromethane, washed with
brine, dried over Na2SO4, filtered, and evaporated in vacuo. The
crude products were purified by chromatography on silica gel, using
as eluent petroleum ether/ethyl acetate 2:1 (v/v). After recrystalliza-
tion from diethyl ether, the acetic esters 5 and 6 were obtained.
4.1.5.1. Ethyl 2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (5). White powder, mp
164 C (65% yield). 1H NMR (400 MHz, CDCl3) d ppm: 7.66 (d, 2H,
–C–CH–CH), 7.38–7.34 (m, 1H, CH–CH–CH), 7.13–7.10 (m, 1H, N–
C–CH–C–F), 7.08 (d, 2H, S–C–CH–CH), 6.96 (d, 2H, C–CH–CH),6.45 (s, 1H, CH pyrrolic), 4,86 (s, broad, 2H, NH2), 4.08 (q, 2H,
OCH2–CH3), 3.48 (s, 2H, C–CH2–CO), 2.01 (s, 3H, CH3 pyrrolic),
1.20 (t, 3H, CH2CH3). 13C NMR (100 MHz, CDCl3) d (ppm): 169.2
(CO–O), 163.8 (C–F), 144.8 (S–C), 143.7 (N–C–CH), 142.3 (CH–C–
CH), 134.2 (N–C–C), 131.4 (CH–CH–CH), 129.3 (CH–C–S), 128.6
(C–CH–CH), 125.9 (N–C–CH3), 122.3 (C–CH2), 116.1 (N–C–CH–
CH), 113.5 (CH pyrrolic), 111.9 (CH–CH–C–F), 107.4 (F–C–CH–C–
N), 61.3 (O–CH2CH3), 34.2 (CH2–CO), 13.6 (CH2–CH3), 10.8 (CH3
pyrrolic). MS-ESI: m/z 439.11 [M+Na]+.
4.1.5.2. Ethyl 2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (6). White powder, mp
149 C (65% yield). 1H NMR (400 MHz, CDCl3) d ppm: 7.67 (d, 2H,
–C–CH–CH), 7.13–7.08 (m, 6H, H aromatic), 6.50 (s, 1H, CH pyrro-
lic), 4.72 (s broad, 2H, NH2), 4.20 (q, 2H, OCH2–CH3), 3.51 (s, 2H, C–
CH2–CO), 2.06 (s, 3H, CH3 pyrrolic), 1.29 (t, 3H, CH2CH3). 13C NMR
(100 MHz, CDCl3) d (ppm): 169.1 (CO–O), 160.9 (C–F), 146.8 (N–C–
CH), 143.4 (S–C), 142.5 (CH–C–CH), 134.4 (N–C–C), 128.8 (CH–C–
S), 127.7 (C–CH–CH), 125.6 (N–C–CH3), 122.3 (N–C–CH–CH),
121.4 (C–CH2 pyrrolic), 116.2 (CH–CH–C–F), 113.3 (CH pyrrolic),
61.4 (O–CH2CH3), 34.5 (CH2–CO), 14.6 (CH2–CH3), 10.2 (CH3 pyrro-
lic). MS-ESI: m/z 439.11 [M+Na]+.
4.1.6. General procedure for the preparation of 1,5-diarylpyrrol
acetic acids 7 and 8
After dissolution of the appropriate acetic ester (5 and 6)
(1.3 mmol) in ethanol (9.4 mL), a solution of NaOH (0.38 g) in
water (9.4 mL) was added dropwise. The mixture was refluxed
for two hours and then the residue was solubilized in water
(5 mL) and then concentrated HCl was added dropwise until a pre-
cipitate was formed. The precipitate was filtered off to give the
expected acids 7 and 8 as white solids.
4.1.6.1. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)acetic acid (7). White powder, mp 182 C
(>90% yield). 1H NMR (400 MHz, DMSO-d6) d ppm: 12.17 (s broad,
1H, COOH), 7.59 (d, 2H, –C–CH–CH), 7.28–7.25 (m, 4H, H aromatic),
7.22 (s broad, 2H, SO2NH2), 7.10 (d, 2H, S–C–CH–CH), 7.04–7.03 (m,
1H, CH–CH–C–F), 6.46 (s, 1H, CH pyrrolic), 3.31 (s, 2H, C–CH2–CO),
2.01 (s, 2H, CH3 pyrrolic). 13C NMR (100MHz, DMSO-d6) d (ppm):
176.3 (CO–O), 163.5 (C–F), 143.8 (S–C), 142.9 (N–C–CH), 142.0 (CH–
C–CH), 134.2 (N–C–C), 130.6 (CH–CH–CH), 128.1 (CH–C–S), 127.8
(C–CH–CH), 125.4 (N–C–CH3), 121.3 (C–CH2), 116.1 (N–C–CH–CH),
113.3 (CH pyrrolic), 112.0 (CH–CH–C–F), 107.2 (F–C–CH–C–N), 36.2
(CH2–CO), 10.2 (CH3 pyrrolic). MS-ESI: m/z 411.08 [M+ Na]+.
4.1.6.2. 2-(1-(4-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)acetic acid (8). 1H NMR (400 MHz, DMSO-d6)
d ppm: 12.15 (s broad, 1H, COOH), 7.59 (d, 2H, –C–CH–CH), 7.35–
7.30 (m, 4H, H aromatic), 7.27 (s broad, 2H, SO2NH2), 7.13 (d, 2H,
S–C–CH–CH), 6.48 (s, 1H, CH pyrrolic), 3.41 (s, 2H, C–CH2–CO),
2.03 (s, 3H, CH3 pyrrolic).13C NMR (100 MHz, DMSO-d6) d (ppm):
176.1 (CO–O), 157.3 (C–F), 146.8 (N–C–CH), 142.4 (S–C), 142.0
(CH–C–CH), 134.1 (N–C–C), 127.8 (CH–C–S), 126.4 (C–CH–CH),
125.0 (N–C–CH3), 121.3 (N–C–CH–CH), 119.3 (C–CH2 pyrrolic),
116.1 (CH–CH–C–F), 113.3 (CH pyrrolic), 35.8 (CH2–CO), 10.1
(CH3 pyrrolic). MS-ESI: m/z 411.08 [M+Na]+
4.1.7. General procedure for the preparation of 4-sulfamoylphenyl
acetamides 9–12
To a solution of the suitable acetic acid (7 and 8) (0.51 mmol) in
a mixture of dichloromethane/DCM 10:1 (v/v) under nitrogen flow,
the appropriate amine (2.04 mmol), DMAP (0.61 mmol, 0.07 g) and
EDCI (0.82 mmol, 0.16 g) were added in sequence. The reaction
mixture was stirred at room temperature for 15 h and then it
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dichloromethane. The organic layers were washed with 2 N HCl,
NaHCO3 saturated solution and brine, then was dried Na2SO4, fil-
tered and concentrated in vacuo. The obtained crude products
were purified by column chromatography on silica gel using cyclo-
hexane/ethyl acetate 1:1, as eluent. After recrystallization from
ethyl acetate, the desired products 9–12 were obtained.
4.1.7.1. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)-N-propylacetamide (9). White powder, mp
192 C (yield 60%). 1H NMR (400 MHz, DMSO-d6) d ppm: 7.85 (t,
1H, NH), 7.57 (d, 2H, –C–CH–CH), 7.50–7.45 (m, 1H, CH–CH–CH),
7.31–7.29 (m, 1H, N–C–CH–CH),7.24 (s broad, 2H, SO2NH2), 7.20–
7.17 (m, 1H, N–C–CH–C–F), 7.12 (d, 2H, S–C–CH–CH), 7.02 (d, 1H,
CH–CH–C–F), 6.44 (s, 1H, CH pyrrolic), 3.23 (s, 2H, C–CH2–CO),
3.01 (m, 2H, N–CH2–CH2), 2.02 (s, 3H, CH3 pyrrolic), 1.44 (sest,
2H, CH2–CH2–CH3), 0.84 (t, 3H, CH2–CH3). 13C NMR (100 MHz,
DMSO-d6) d (ppm): 171.8 (CO–O), 164.8 (C–F), 144.2 (S–C), 143.8
(N–C–CH), 143.1 (CH–C–CH), 134.9 (N–C–C), 131.2 (CH–CH–CH),
127.9 (CH–C–S), 127.6 (C–CH–CH), 126.4 (N–C–CH3), 121.8 (C–
CH2), 117.5 (N–C–CH–CH), 113.8 (CH pyrrolic), 112.7 (CH–CH–C–
F), 108.0 (F–C–CH–C–N), 43.3 (NH–CH2–CH2), 34.6 (CH2–CO),
23.5 (CH2–CH2–CH3), 11.8 (CH2–CH3), 10.2 (CH3 pyrrolic). MS-ESI:
m/z 452.14 [M+Na]+.
4.1.7.2. 2-(1-(4-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)-N-propylacetamide (10). White powder, mp
183 C (yield 60%). 1H NMR (400 MHz, DMSO-d6) d ppm: 7.86 (t,
1H, t, 1H, NH), 7.58 (d, 2H, –C–CH–CH), 7.31–7.25 (m, 4H, H aro-
matic), 7.24 (s broad, 2H, SO2NH2), 7.11 (d, 2H, S–C–CH–CH),
6.44 (s, 1H, CH pyrrolic), 3.24 (s, 2H, C–CH2–CO), 3.02 (m. 2H, N–
CH2–CH2), 2.00 (s, 3H, CH3 pyrrolic), 1.43 (sest, 2H, CH2–CH2–
CH3), 0.85 (t, 3H, CH2–CH3). 13C NMR (100 MHz, DMSO-d6) d
(ppm): 171.2 (CO–O), 159.3 (C–F), 146.6 (N–C–CH), 143.3 (S–C),
142.0 (CH–C–CH), 133.9 (N–C–C), 129.2 (CH–C–S), 128.0 (C–CH–
CH), 125.8 (N–C–CH3), 121.8 (N–C–CH–CH), 121.0 (C–CH2 pyrrolic),
115.8 (CH–CH–C–F), 112.6 (CH pyrrolic), 42.5 (NH–CH2–CH2), 33.8
(CH2–CO), 23.0 (CH2–CH2–CH3), 11.0 (CH2–CH3), 9.8 (CH3 pyrrolic).
MS-ESI: m/z 451.15 [M+Na]+.
4.1.7.3. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)-N-isopropylacetamide (11). 1H NMR
(400 MHz, DMSO-d6) d ppm: 7.81 (d, 1H, NH), 7.58 (d, 2H,
–C–CH–CH), 7.48–7.46 (m, 1H, CH–CH–CH), 7.32–7.30 (m, 1H, N–
C–CH–CH), 7.25 (s broad, 2H, SO2NH2), 7.21–7.18 (m, 1H, N–C–
CH–C–F), 7.12 (d, 2H, S–C–CH–CH), 7.01 (d, 1H, CH–CH–C–F),
6.43 (s, 1H, CH pyrrolic), 3.85–3.79 (set, 1H, CH3–CH–CH3), 3.20
(s, 2H, C–CH2–CO), 1.98 (s, 3H, CH3 pyrrolic), 1.06 (d, 6H, CH–
CH3). 13C NMR (100 MHz, DMSO-d6) d (ppm): 171.3 (CO–O),
164.2 (C–F), 143.7 (S–C), 143.5 (N–C–CH), 143.0 (CH–C–CH),
134.4 (N–C–C), 131.3 (CH–CH–CH), 130.0 (CH–C–S), 127.9 (C–
CH–CH), 126.2 (N–C–CH3), 121.6 (C–CH2), 117.1 (N–C–CH–CH),
113.1 (CH pyrrolic), 112.2 (CH–CH–C–F), 107.5 (F–C–CH–C–N),
44.3 (NH–CH), 34.5 (CH2–CO), 23.1 (CH–CH3), 9.8 (CH3 pyrrolic).
MS-ESI: m/z 452.14 [M+Na]+.
4.1.7.4. 2-(1-(4-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-
1H-pyrrol-3-yl)-N-isopropylacetamide (12). White powder,
mp 194 C (yield 60%). 1H NMR (400 MHz, DMSO-d6) d ppm: 7.78
(t, 1H, NH), 7.57 (d, 2H, –C–CH–CH), 7.29–7.25 (m, 4H, H aromatic),
7.23 (s broad, 2H, SO2NH2), 7.10 (d, 2H, S–C–CH–CH), 6.41 (s, 1H,
CH pyrrolic), 3.84–3.79 (set, 1H, CH3–CH–CH3), 3.19 (s, 2H, C–
CH2–CO), 1.98 (s, 3H, CH3 pyrrolic), 1.05 (d, 6H, CH–CH3). 13C
NMR (100 MHz, DMSO-d6) d (ppm): 171.3 (CO–O), 159.7 (C–F),
147.2 (N–C–CH), 143.5 (S–C), 142.8 (CH–C–CH), 134.3 (N–C–C),
129.2 (CH–C–S), 127.7 (C–CH–CH), 126.4 (N–C–CH3), 122.3(N–C–CH–CH), 121.2 (C–CH2 pyrrolic), 116.3 (CH–CH–C–F), 113.3
(CH pyrrolic), 44.5 (NH–CH), 34.8 (CH2–CO), 23.2 (CH–CH3), 10.0
(CH3 pyrrolic). MS-ESI: m/z 452.14 [M+Na]+.
4.2. Biology and pharmacology
4.2.1. In vitro anti-inflammatory studies
The inhibitory activity of compounds 1–12 against both cyclo-
oxygenases, COX-1 and COX-2, was determined by the commer-
cially available COX Inhibitor Screening Assay (Cayman
Chemical, Ann Arbor, MI, USA, catalogue no. 560131), which
exploits an enzyme immunoassay to measure PGE2a produced
by stannous chloride reduction of PGEH2, derived in turn by reac-
tion between the target enzyme and the substrate, arachidonic
acid. According to manufacture’s protocol, test compounds
(10 lL) were incubated for 10 min at 37 C with assay buffer
(0.1 M Tris–HCl, pH 8, 160 lL), Heme (10 lL), and either ovine
COX-1 or human recombinant COX-2 enzyme solution (10 lM).
Arachidonic acid (10 lL) was then added, and the resulting mix-
ture was incubated for 2 min at 37 C. Enzyme catalysis was
stopped by adding HCl (1 M, 10 mL) and the obtained PGEH2
were converted to PGE2a with saturated stannous chloride solu-
tion (20 lL). Prostanoids were finally quantified by EIA and their
amount was determined through interpolation from a standard
curve. The % inhibition of target enzyme by test compounds
was calculated by comparing PGE2a produced in compound-trea-
ted samples with that of the compound-free, control sample. The
highly selective COX-1 inhibitor SC-560 and the highly selective
COX-2 inhibitor Dup-697 were used as reference compounds.
All the test compounds, 1–12, were dissolved into dilute assay
buffer, and their solubility was facilitated by using DMSO, whose
concentration never exceeded 1% in the final reaction mixture.
The inhibitory effect of test compounds was routinely estimated
at a concentration of 10 lM. Those compounds found to be active
were tested at additional concentrations between 10 lM and
10 nM. The determination of the IC50 values was performed by
linear regression analysis of the log-dose response curve, which
was generated using at least five concentrations of the inhibitor
causing an inhibition between 10% and 90%, with three replicates
at each concentration (Table 1).
4.2.2. In vivo analgesic and anti-inflammatory study
The analgesic activity of compounds was assessed by perform-
ing the abdominal constriction test, using mice Male Swiss albino
mice (23–25 g) and Sprague-Dawley or Wistar rats (150–200 g).
The animals were fed with a standard laboratory diet and tap
water ad libitum and kept at 23 (1 C with a 12 h light/dark cycle,
light on at 7 a.m.). Mice had been injected intra-peritoneal (ip)
with a 0.6% solution of acetic acid (10 mL/kg). The number of
stretching movements was counted for 10 min, starting 5 min after
administration.
4.3. Molecular modeling
Any calculation was performed using a 6 blade (8 Intel-Xeon
E5520 2.27 GHz CPU and 24 GB DDR3 RAM) running Debian
GNU/Linux ‘‘Wheezy’’ 7.5 64 bit operating system.
4.3.1. Molecular docking
Molecular docking calculations were carried out with several
programs selected among those as open source or free to academ-
ics: Autodock,26 Vina,27 Plants,28 PARADOCKS29 and Surflex-
Dock.20
4.3.2. Docking assessment protocol
A cross-docking protocol was set up for eight docking program/
scoring function combination, during the cross-docking each
820 S. Consalvi et al. / Bioorg. Med. Chem. 23 (2015) 810–820ligand extracted from the experimental COX complex was docked
into all the not native proteins for each isoenzyme.
4.3.3. Ligand and protein preparation
The experimental complexes (PDB entries listed in Tables 3 and
4),22 upon hydrogen addition, were minimized by means of
GROMACS30 with the AMBER force field59 in explicit water (box
expanding 10 Å from each external complex coordinate) using
the Powell method with an initial Simplex optimization (500 iter-
ations) followed by 1000 iterations of conjugated gradient termi-
nation at 0.01 kcal/(mol Å). Ligand’s random conformations were
generated from the bound conformation extracted from the mini-
mized COX-1/COX-2 experimental co-crystallized complexes.
Using OpenBabel 2.3.231 version, hydrogen atoms were added,
and charges were loaded using the Gasteiger and Marsili charge
calculation method, then their center of mass were centered at
x,y,z 0.0 coordinates, finally the OpenBabel obconformer tools
was used to generate a minimized random conformation for each
ligand. Input ligands file format was mol2 for all the docking pro-
grams except for Autodock and Vina that required a pdbqt format;
a total of 8 docking/scoring function combinations were used.
4.3.4. AutoDock/Vina setting
Intermediary steps, such as pdbqt files for protein and ligand
preparation were completed using different AutoDock Tools
(ADT) Scripts. AutoGrid was used for the preparation of the grid
map using a grid box. The grid size was expanded 10 Å beyond
any external ligand atoms with grid spacing of 0.375 Å and cen-
tered at the mean molecules’ center of mass. For each calculation,
twenty poses were obtained and ranked according to the scoring-
functions of either Autodock or Vina.
4.3.5. Plants settings
The docking of the target protein with the ligand was performed
using Plants v1.2 version with three different scoring functions at
default speed (SPEED1). The docking tools generated 20 conforma-
tion for each docked ligand. The docking binding site was centered
the molecules’ mean center and enlarging to a radius of 15 Å.
4.3.6. Paradocks settings
Both Paradocks-pscore and Paradocks-pmf04 scoring functions
were used in their default configuration (Iteration 15,000, particle
count 20, constricting the inertia start 1.0, constricting inertia end
0.2, cognitive weight 1.0 and social weight 3.4).
4.3.7. Surflex-Dock settings
Version 2.0.1 of the program was used; the input file was built
using the mol2 prepared protein structure. The protocol was gen-
erated using all the ligands structures with a threshold of 0.50
and bloat set to 0 (default settings). Ligand were prepared as
describes above and docked as mol2 files.
4.3.8. New COX inhibitor preparation and docking
Ligand’s 3D conformations were generated from scratch.
Marvin was used for drawing, displaying and characterizing chem-
ical structures, Marvin 14.7.7.0, 2014, ChemAxon (http://www.
chemaxon.com). For homogeneity purposes, OpenBabel was used
to generate a random conformation similarly as described in the
docking assessment section.
The 1–12 generated random conformations were cross-docked
using Surflex-Dock and Vina for COX-1 and COX-2, respectively.
The same setting used for the docking assessment protocol were
applied. All the protein structures were used in this step.Acknowledgments
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